Text Only
Full media Version

The Emergency Contraception Website - Your website for the "Morning After"

Plan B


In the U.S., progestin-only EC is available on the shelf without age restrictions to women and men. Look for Plan B One-Step, Take Action, Next Choice One-Dose, My Way or other generics in the family planning aisle.

History of Plan B OTC:

  • May 1999: Plan B approved as Rx drug by the FDA
  • April 2003: Application submitted to switch Plan B from Rx to OTC; FDA decision due February 2004
  • December 2003: FDA convenes advisory committee, which votes 23-4 in favor of taking Plan B OTC
  • February 2004: FDA announces that it will delay decision on Plan B up to 90 days
  • May 2004: FDA rejects application to switch Plan B from Rx to OTC, citing lack on data on females younger than 16
  • June 2004: Congress requests report on FDA decision not to switch Plan B from Rx to OTC (report released in October 2005). Report concludes that decision on Plan B was "highly unusual", and may well have been made months before it was formally announced
  • July 2004: Barr Laboratories submits amended application to make Plan B Rx for females older than 16 and OTC otherwise
  • January 2005: Deadline for FDA to respond to Barr’s application
  • July 2005: HHS Secretary Leavitt promises that FDA will act on Barr’s application by September 1, 2005, to ensure a vote on Senate confirmation of Lester Crawford as FDA Commissioner
  • August 2005: FDA announces that Plan B is safe for OTC use by women 17 and older, but announces an indefinite delay, citing three concerns (and allowing a 60-day public comment period on the first two questions):
    • Can Plan B be both Rx and OTC depending on age?
    • Can Rx and OTC versions of Pan B be marketed in the same package?
    • Can an age restriction for Plan B be enforced?
  • July 2006: The day before his confirmation hearing, acting FDA Commissioner Andrew von Eschenbach publicly invites Barr Labs to resubmit its application by changing the OTC age restriction for Plan B to 18 and older
  • August 18, 2022: Barr labs resubmits its application to make Plan B available OTC to consumers 18 and older, and Rx to women aged 17 and younger
  • August 24, 2022: FDA approves making Plan B available OTC to consumers 18 and older and Rx to women aged 17 and younger
  • November 2006: Barr Labs begins shipping Plan B in new packaging to pharmacies
  • March 23, 2022: Federal judge rules that the FDA must make Plan B available OTC to consumers 17 and older within 30 days and urges the agency to consider removing all age restrictions. Read the full text of the decision here
  • April 22, 2022: The FDA announces that Plan B may be sold OTC to women and men aged 17 and older
  • February 7, 2022: Teva submits actual-use study data and label-comprehension study data on females <18 to the FDA

  • December 7, 2021: the FDA is set to approve OTC status for Plan B with no age restriction based on the studies submitted by Teva. However, this action was overruled by the Secretary of Health and Human Services Kathleen Sebelius

  • 2012: Teva files an amended application to make Plan B One-Step available without prescription to consumers aged 15 and over and to allow it to be available in the family planning section of a pharmacy rather than behind the pharmacy counter; proof of age would still be required at checkout.

  • April 5, 2022: U.S. District Judge Edward R. Korman orders the FDA to allow over-the-counter sales of LNg ECPs with no age restriction. Read the decision here.

  • April 30, 2022: the FDA approves Teva’s amended application, allowing sale of Plan B One-Step on the shelf without prescription for women aged 15 and older. Read the FDA press release here.

  • May 1, 2013: U.S. Department of Justice appeals Judge Korman’s April 5 ruling, seeks a stay of this order to remove age and point-of-sale requirements.
  • May 10, 2013: Judge Korman denies DOJ’s request for a stay, reprimands Administration.
  • June 5, 2013: A 3-judge appeals court denies the DOJ’s motion for a stay, demands that 2-pill generic ECPs be made available without restrictions.
  • June 10, 2013: DOJ drops its appeal, agrees to support unrestricted approval of Plan B One-Step if generics remain age-restricted and behind the counter.
  • June 20, 2013: FDA approves Plan B One-Step for unrestricted sale on the shelf.
  • February 25, 2014: FDA approves generic one-pill EC products for unrestricted sale on the shelf. Read the letter here.








This website is operated by the Office of Population Research at Princeton University and has no connection with any pharmaceutical company or for-profit organization.

website design by DDA